Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Opthea Limited ( (AU:OPT) ) has provided an update.
Opthea Limited announced its participation in the Oppenheimer Healthcare Life Sciences Conference, with CEO Frederic Guerard set to present and engage in one-on-one meetings. This participation underscores Opthea’s active role in advancing its Phase 3 product, sozinibercept, which has the potential to revolutionize treatment for wet AMD, thereby reinforcing its position in the biopharmaceutical industry and offering significant implications for stakeholders.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases like wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Their lead product candidate, sozinibercept, a VEGF-C/D ‘trap’ inhibitor, is in Phase 3 development and aims to improve the quality of life for patients with wet AMD by enhancing standard anti-VEGF-A treatments.
YTD Price Performance: 9.09%
Average Trading Volume: 9,900
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $848.6M
See more data about OPT stock on TipRanks’ Stock Analysis page.